Biology subjects

Croze, S.

Publications and source records attributed to Croze, S..

2 recordsLinked to original sources

bioRxiv2025

NAD metabolism plays multiple roles in influenza A virus replication in a novel ex vivo model of mouse lung infection.

Despite the availability of prophylactic and therapeutic measures, Influenza A viruses (IAV) remain a major public health concern, causing an estimated 650 000 deaths annually. In this context, the identification of metabolic vulnerabilities of IAV replication could help develop complements to existing antiviral strategies. Here, we used nicotinamide phosphoribosyltransferase (NAMPT) inhibitors to demonstrate that nicotinamide adenine dinucleotide (NAD) is essential for IAV replication and infectious particles production both in vitro and ex vivo. We established an innovant ex vivo model of murine organotypic lung cultures (mOLC) that is pertinent to analyze cell metabolic alterations triggered by IAV infection. Using untargeted metabolomic profiling and spatial transcriptomic analyses, our research revealed that IAV-infection decreased NAD+ levels in mOLCs, while PARPs, a group of NAD+-consuming enzymes, were upregulated. Pharmacological inhibition of the mono-ADP-ribosyl-transferase (mono-ART) activity of PARPs restricted IAV infection ex vivo, suggesting that NAD+ sustains the proviral activity of these enzymes. Overall, our study identifies NAD metabolism as a central regulator of IAV infection, providing redox cofactor to host cell biosynthetic processes and substrate for mono-ART activity. Our results highlight NAMPT and PARP mono-ART activity as promising antiviral targets. Significance StatementViruses are intracellular parasites that rely on the host cellular metabolism for their replication. Our results demonstrate that Influenza A virus (IAV) replication is critically dependent on NAD availability, an enzyme cofactor essential for redox metabolic reactions and a substrate for NAD+-consuming enzymes. Using a novel ex vivo infection model of mouse lung tissue, we found that IAV infection results in NAD depletion and enhanced expression of NAD-consuming PARP enzymes. Inhibitors of NAD biosynthesis and mono(ADP-ribosyl) transferase activity of PARP are restricting viral replication and infectious particles production. These findings highlight the proviral role for PARP mono-ART activity and identify NAMPT and PARP inhibitors as potential host-directed antivirals against IAV.

microbiology↗

bioRxiv2018

Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

BackgroundInfluenza virus infections remain a major and recurrent public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the critical need for novel therapeutic approaches. In this context, the aim of this study was to develop and validate an innovative strategy for drug repurposing as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most promising candidates in Phase II clinical trials.\n\nMethodsWe exploited in vivo global transcriptomic signatures of infection directly obtained from a patient cohort to determine a shortlist of already marketed drugs with newly identified, host-targeted inhibitory properties against influenza virus. The antiviral potential of selected repurposing candidates was further evaluated in vitro, in vivo and ex vivo.\n\nResultsOur strategy allowed the selection of a shortlist of 35 high potential candidates out of a rationalized computational screening of 1,309 FDA-approved bioactive molecules, 31 of which were validated for their significant in vitro antiviral activity. Our in vivo and ex vivo results highlight diltiazem, a calcium channel blocker currently used in the treatment of hypertension, as a promising option for the treatment of influenza infections. Additionally, transcriptomic signature analysis further revealed the so far undescribed capacity of diltiazem to modulate the expression of specific genes related to the host antiviral response and cholesterol metabolism. Finally, combination treatment with diltiazem and virus-targeted oseltamivir neuraminidase inhibitor further increased antiviral efficacy, prompting rapid authorization for the initiation of a Phase II clinical trial.\n\nConclusionsThis original, host-targeted, drug repurposing strategy constitutes an effective and highly reactive process for the rapid identification of novel anti-infectious drugs, with potential major implications for the management of antimicrobial resistance and the rapid response to future epidemic or pandemic (re)emerging diseases for which we are still disarmed.

microbiology↗